CLINICAL TRIALS PROFILE FOR KALYDECO
✉ Email this page to a colleague
All Clinical Trials for kalydeco
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01614457 ↗ | Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT) | Completed | Cystic Fibrosis Foundation | Phase 3 | 2012-07-01 | The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have the R117H-CFTR mutation. |
NCT01614457 ↗ | Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT) | Completed | Cystic Fibrosis Foundation Therapeutics | Phase 3 | 2012-07-01 | The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have the R117H-CFTR mutation. |
NCT01614457 ↗ | Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT) | Completed | Vertex Pharmaceuticals Incorporated | Phase 3 | 2012-07-01 | The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have the R117H-CFTR mutation. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for kalydeco
Condition Name
Clinical Trial Locations for kalydeco
Trials by Country
Clinical Trial Progress for kalydeco
Clinical Trial Phase
Clinical Trial Sponsors for kalydeco
Sponsor Name